Rilmazafone Powder

Rilmazafone, systematically named 5-[[(2-aminoacetyl)amino]methyl]-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1H-1,2,4-triazole-3-carboxamide (molecular formula C₂₁H₂₀Cl₂N₆O₃, CAS: 99593-25-6, molecular weight 475.33 g/mol), is a unique water-soluble prodrug featuring a substituted triazole-carboxamide core linked to a dichlorobenzophenone moiety via a glycylamino side chain. This non-benzodiazepine scaffold undergoes enzymatic ring closure and metabolic transformation in biological systems to yield active triazolobenzodiazepine metabolites, most notably rilmazolam (and its desmethyl derivatives), which structurally resemble classical triazolo analogs such as alprazolam.

Supplied as a high-purity, fine white to off-white crystalline powder, our rilmazafone is synthesized and verified exclusively for in vitro laboratory research, analytical reference standard use, forensic profiling, metabolic pathway elucidation, prodrug activation studies, and neuropharmacological investigations into GABA_A receptor modulation via indirect mechanisms.

As a prodrug with negligible intrinsic affinity for benzodiazepine binding sites, rilmazafone serves as an intriguing research tool for examining aminopeptidase-mediated bioactivation, metabolite formation kinetics, structure-metabolism relationships in heterocyclic systems, comparative hypnotic/sedative profiles, and differential effects on motor coordination versus sleep induction in controlled experimental models.